Clinical Trials
Participation in clinical research advances our knowledge of effective treatments and helps us understand the life cycle of diseases.
Inspire Santa Fe Medical is committed to offering our patients the latest treatments through our clinical research division. Every clinical study is monitored and closely follows all FDA clinical practice guidelines for investigating the efficacy of new medications not yet on the market, as well as new uses for existing medications on the market.
Inclusion and involvement in any clinical study are voluntary and may be discontinued at any time by either the participant or study sponsor. Study participants are provided full disclosure of the study parameters, purpose, duration, and side effects If you are interested in learning more about a current trial or upcoming research participation opportunities, please contact us. Our experienced research team will be happy to discuss and answer questions you or your family may have about study objectives.
We are actively recruiting for the following clinical trials:
RA-PROPR: A Real-World Comparative Effectiveness Trial of Treatment Strategies in Patients With Rheumatoid Arthritis: The RA-PRO Pragmatic Trial (RA-PROPR)
Sanofi ACT17010: Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study
Takeda TAK-279-PsA-3001: A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naïve to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001).
Merck MK7240-013: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants With Radiographic Axial Spondyloarthritis (Ankylosing Spondylitis).
We are participating in the following trials, but recruitment has ended:
Lilly-I4V-MC-JAJA: A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Horizon HZNP-KRY-409: A Phase 4, Randomized, Double-blind, Multicenter Non-inferiority Trial Evaluating the Efficacy and Safety of Intravenous KRYSTEXXA® (pegloticase) Administered Every 4 Weeks Compared with KRYSTEXXA Administered Every 2 Weeks with Co-administration of Weekly Doses of Methotrexate, Followed by an Open-label Extension, in Participants with Uncontrolled Refractory Gout (FORWARD II)
Ely Lilly I1F-MC-RHDB: Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA).
Sanofi DRI17821: A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety study of SAR441566 plus Methotrexate in Adults with Moderate-to-Severe Rheumatoid Arthritis.